VVWCISOLOWMSAD-UHFFFAOYSA-N
C33H28FN9O4 — CID 121249749
Data last refreshed: (MolForge compound catalog, from PubChem)
About VVWCISOLOWMSAD-UHFFFAOYSA-N
VVWCISOLOWMSAD-UHFFFAOYSA-N (PubChem CID 121249749) has the molecular formula C33H28FN9O4 and a molecular weight of 633.64 g/mol. Its IUPAC name is 5-tert-butyl-N-[[4-[2-[1-[2-(1,3-dioxoisoindol-2-yl)ethyl]pyrazol-4-yl]-1H-imidazo[4,5-b]pyridin-7-yl]-2-fluorophenyl]methyl]-1,2,4-oxadiazole-3-carboxamide.
Molecular Properties
| Compound Name | VVWCISOLOWMSAD-UHFFFAOYSA-N |
|---|---|
| PubChem CID | 121249749 |
| Molecular Formula | C33H28FN9O4 |
| Molecular Weight | 633.64 g/mol |
| Exact Mass | 633.22 |
| IUPAC Name | 5-tert-butyl-N-[[4-[2-[1-[2-(1,3-dioxoisoindol-2-yl)ethyl]pyrazol-4-yl]-1H-imidazo[4,5-b]pyridin-7-yl]-2-fluorophenyl]methyl]-1,2,4-oxadiazole-3-carboxamide |
| SMILES | CC(C)(C)c1nc(C(=O)NCc2ccc(-c3ccnc4nc(-c5cnn(CCN6C(=O)c7ccccc7C6=O)c5)[nH]c34)cc2F)no1 |
| InChI | InChI=1S/C33H28FN9O4/c1-33(2,3)32-40-28(41-47-32)29(44)36-15-19-9-8-18(14-24(19)34)21-10-11-35-27-25(21)38-26(39-27)20-16-37-42(17-20)12-13-43-30(45)22-6-4-5-7-23(22)31(43)46/h4-11,14,16-17H,12-13,15H2,1-3H3,(H,36,44)(H,35,38,39) |
| InChIKey | VVWCISOLOWMSAD-UHFFFAOYSA-N |
| XLogP | 4.53 |
| TPSA | 164.79 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 10 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 47 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 633.64 |
| LogP ≤ 5 | 4.53 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 10 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'phthalimide', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 121249749 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.